LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 194

Search options

  1. Article ; Online: MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?

    Gökbuget, Nicola

    Hematology. American Society of Hematology. Education Program

    2022  Volume 2021, Issue 1, Page(s) 718–725

    Abstract: Evaluation of minimal residual disease (MRD) during first-line treatment and after salvage therapy is part of the standard management of acute lymphoblastic leukemia (ALL). Persistent or recurrent MRD is one of the most relevant prognostic factors and ... ...

    Abstract Evaluation of minimal residual disease (MRD) during first-line treatment and after salvage therapy is part of the standard management of acute lymphoblastic leukemia (ALL). Persistent or recurrent MRD is one of the most relevant prognostic factors and identifies a group of patients with resistance to standard chemotherapy. These patients have a high risk of relapse despite continued first-line therapy. Although stem cell transplantation (SCT) is an appropriate strategy, patients with high MRD show an increased relapse rate even after SCT. Approximately one-quarter of adult ALL patients develop an MRD failure, defined as MRD above 0.01% after standard induction and consolidation. The best time point and level of MRD for treatment modification are matters of debate. In order to eradicate MRD and thereby improve chances for a cure, new targeted compounds with different mechanisms of action compared to chemotherapy are being utilized. These compounds include monoclonal antibodies, chimeric antigen receptor T cells, and molecular targeted compounds. Essential factors for decision-making, available compounds, and follow-up therapies are discussed.
    MeSH term(s) Adult ; Hematopoietic Stem Cell Transplantation ; Humans ; Neoplasm, Residual ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Prognosis ; Recurrence ; Treatment Outcome
    Language English
    Publishing date 2022-01-27
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2021000224
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book: L-Asparaginase

    Gökbuget, Nicola / Attarbaschi, Andishe

    akute lymphatische Leukämie (ALL) bei Erwachsenen

    (Drug report ; 11. Jahrgang, Heft 6 (April 2017))

    2017  

    Author's details Autor: Dr. med. Nikola Gökbuget, Dr. med. Andishe Attarbaschi
    Series title Drug report ; 11. Jahrgang, Heft 6 (April 2017)
    Collection
    Language German
    Size 11 Seiten, Illustrationen, 28 cm
    Publisher Thieme
    Publishing place Stuttgart
    Publishing country Germany
    Document type Book
    HBZ-ID HT019371963
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    Zs A 6601 -11,6- verfügbar in Königswinter Königswinter

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book ; Online: Blinatumomab (neues Anwendungsgebiet, Ph+ ALL)

    Wörmann, Bernhard / Gökbuget, Nicola / Pfeifer, Heike

    Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln für seltene Leiden gemäß § 35a SGB V, veröffentlicht am 3. Mai 2021, Vorgangsnummer 2021-02-01-D-610, IQWiG Bericht Nr. 1091

    2021  

    Institution GMALL
    Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
    Deutschland / Gemeinsamer Bundesausschuss
    Author's details DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie; GMALL - German Multicenter Study Group on Adult Acute Lymphoblastic Leukemia; Gemeinsamer Bundesausschuss ; die Stellungnahme wurde von Prof. Dr. Bernhard Wörmann in Kooperation mit Dr. Nicola Gökbuget und Dr. Heike Pfeifer (Johann Wolfgang Goethe-Universität, Medizinische Klinik II, Abteilung Hämatologie und Onkologie, Frankfurt) erarbeitet
    Subject code 610
    Language German
    Size 1 Online-Ressource (7 Seiten)
    Publisher DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
    Publishing place Berlin
    Publishing country Germany
    Document type Book ; Online
    Note Open Access
    HBZ-ID HT021710060
    DOI 10.4126/FRL01-006440089
    Database Repository for Life Sciences

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Book: Recommendations of the European working group for adult ALL

    Gökbuget, Nicola

    (UNI-MED science)

    2011  

    Author's details [Nicola Gökbuget (ed. in chief)]
    Series title UNI-MED science
    Keywords Akute lymphatische Leukämie ; Therapie
    Subject Medizinische Behandlung ; Behandlung ; Krankenbehandlung ; Akute lymphoblastische Leukämie ; ALL
    Subject code 616.9941906
    Language English
    Size 206 S. : Ill., graph. Darst., 25 cm
    Edition 1. ed.
    Publisher UNI-MED-Verl
    Publishing place Bremen u.a.
    Publishing country Germany
    Document type Book
    Note Literaturangaben
    HBZ-ID HT017311918
    ISBN 978-3-8374-1299-4 ; 978-1-84815-178-9 ; 3-8374-1299-7 ; 1-84815-178-0
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2012 A 2937 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Clinical Experience with Bispecific T Cell Engagers.

    Gökbuget, Nicola

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer

    2019  Volume 214, Page(s) 71–91

    Abstract: Bispecific T cell engagers are antibody constructs directed to a tumor-specific target on the one hand and to CD3-positive T cells on the other hand. Blinatumomab is a compound with specificity for the pan-B cell marker CD19. Clinical activity was tested ...

    Abstract Bispecific T cell engagers are antibody constructs directed to a tumor-specific target on the one hand and to CD3-positive T cells on the other hand. Blinatumomab is a compound with specificity for the pan-B cell marker CD19. Clinical activity was tested in relapsed and refractory (R/R) non-Hodgkin's Lymphoma (NHL), R/R acute lymphoblastic leukemia (ALL), and ALL patients with minimal residual disease. Trials have already been started in de novo ALL. The most clinically relevant toxicities are neurologic events and cytokine release syndrome as with other T cell-activating therapies. The mechanisms of resistance are not fully understood. Higher leukemia load and later stage disease represent unfavorable factors. Besides, an upregulation of regulatory T cells and inhibitory molecules like PD-1/PD-L1 may have a role as the loss of target by several mechanisms. The future will show whether the use of bispecifics in ALL can change the standard treatment algorithms and whether bispecific T cell engagers will also be successfully used in other malignant entities.
    MeSH term(s) Antibodies, Bispecific/pharmacology ; Antigens, CD19 ; Clinical Trials as Topic ; Humans ; Lymphoma, Non-Hodgkin/therapy ; Neoplasm, Residual/therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; T-Lymphocytes/cytology
    Chemical Substances Antibodies, Bispecific ; Antigens, CD19 ; blinatumomab (4FR53SIF3A)
    Language English
    Publishing date 2019-08-17
    Publishing country Germany
    Document type Journal Article ; Review
    ISSN 0080-0015
    ISSN 0080-0015
    DOI 10.1007/978-3-030-23765-3_2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Book: Die akute lymphatische Leukämie (ALL) des Erwachsenen

    Gökbuget, Nicola / Hehn, Sina / Wolf, A.

    wissenswerte Informationen rund um die ALL für Patienten und Angehörige : Symptome, Diagnose, Behandlungsmöglichkeiten, häufige Fragen

    2016  

    Author's details N. Gökbuget, S. Hehn, A. Wolf ; Herausgeber: Kompetenznetz Leukämien, Informationszentrum - Kompetenznetz "Akute und chronische Leukämien"; uct, Universitäres Centrum für Tumorerkrankungen Frankfurt
    Language German
    Size 62 Seiten, Illustrationen, 21 cm
    Edition Ausgabe 09/2016
    Publisher Leukämiehilfe Rhein-Main e.V. (LHRM)
    Publishing place Rüsselsheim
    Publishing country Germany
    Document type Book
    HBZ-ID HT020048452
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2009 A 12329 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Book ; Online: Die akute lymphatische Leukämie (ALL) des Erwachsenen

    Gökbuget, Nicola / Hehn, Sina / Wolf, A.

    wissenswerte Informationen rund um die ALL für Patienten und Angehörige : Symptome, Diagnose, Behandlungsmöglichkeiten, häufige Fragen

    2016  

    Author's details N. Gökbuget, S. Hehn, A. Wolf ; Herausgeber: Kompetenznetz Leukämien, Informationszentrum - Kompetenznetz "Akute und chronische Leukämien", uct, Universitäres Centrum für Tumorerkrankungen Frankfurt
    Language German
    Size 1 Online-Ressource (62 Seiten), Illustrationen
    Edition Ausgabe 09/2016
    Publisher Leukämiehilfe Rhein-Main e.V. (LHRM)
    Publishing place Rüsselsheim
    Publishing country Germany
    Document type Book ; Online
    Note Open Access
    HBZ-ID HT019969333
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Treatment of Older Patients with Acute Lymphoblastic Leukaemia.

    Gökbuget, Nicola

    Drugs & aging

    2018  Volume 35, Issue 1, Page(s) 11–26

    Abstract: The outcome of adult acute lymphoblastic leukaemia (ALL) has improved significantly during the past decade, mainly due to intensive paediatric-based chemotherapy. Less improvement has been observed in older patients. A significantly lower rate of ... ...

    Abstract The outcome of adult acute lymphoblastic leukaemia (ALL) has improved significantly during the past decade, mainly due to intensive paediatric-based chemotherapy. Less improvement has been observed in older patients. A significantly lower rate of complete remissions, higher early mortality, higher relapse rate and poorer survival is observed in older compared with younger ALL patients. Most importantly, intensive chemotherapy with or without stem-cell transplantation is less well tolerated in older patients. In addition, there is an increasing incidence of poor prognostic factors with increasing age. Progress has been made with the development of age-adapted, moderately intensive chemotherapy protocols for Ph/BCR-ABL-negative ALL and combinations of tyrosine kinase inhibitors with chemotherapy in Ph/BCR-ABL-positive ALL. Future progress can be expected from new targeted therapies, particularly novel immunotherapies, moderately intensified consolidation strategies and reduced intensity stem-cell transplantation. For this purpose, prospective clinical trials for older patients are urgently needed.
    MeSH term(s) Age Factors ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy ; Middle Aged ; Neoplasm Recurrence, Local ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Prospective Studies ; Stem Cell Transplantation ; Treatment Outcome
    Language English
    Publishing date 2018
    Publishing country New Zealand
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1075770-3
    ISSN 1179-1969 ; 1170-229X
    ISSN (online) 1179-1969
    ISSN 1170-229X
    DOI 10.1007/s40266-017-0503-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3481: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Book ; Online: Akute Lymphatische Leukämie (ALL)

    Gökbuget, Nicola / Baldus, Claudia / Brüggemann, Monika / Hauswirth, Alexander / Schanz, Urs / Machherndl-Spandl, Sigrid / Stelljes, Matthias / Topp, Max S.

    Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen : ICD-10: C91.00

    (Onkopedia Leitlinien)

    2022  

    Abstract: Die Akute Lymphatische Leukämie (ALL) ist eine seltene maligne, hämatologische Erkrankung. Der Häufigkeitsgipfel liegt im Kindesalter. Diese Empfehlungen beziehen sich auf die ALL im Erwachsenenalter. Das klinische Bild der ALL ist charakterisiert durch ... ...

    Institution Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie
    Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie
    Schweizerische Gesellschaft für Medizinische Onkologie
    Schweizerische Gesellschaft für Hämatologie
    Author's details DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V., OeGHO - Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie, SSMO/SSOM/SGMO - Schweizerische Gesellschaft für Medizinische Onkologie, SGH-SSH - Schweizerische Gesellschaft für Hämatologie/Société Suisse d'Hématologie ; Autoren: Nicola Gökbuget, Claudia Baldus, Monika Brüggemann, Alexander W. Hauswirth, Urs Schanz, Sigrid Machherndl-Spandl, Matthias Stelljes, Max Topp
    Series title Onkopedia Leitlinien
    Abstract Die Akute Lymphatische Leukämie (ALL) ist eine seltene maligne, hämatologische Erkrankung. Der Häufigkeitsgipfel liegt im Kindesalter. Diese Empfehlungen beziehen sich auf die ALL im Erwachsenenalter. Das klinische Bild der ALL ist charakterisiert durch die Proliferation und Akkumulation maligner entarteter, unreifer lymphatischer Blasten in Knochenmark, Blut, lymphatischem und nichtlymphatischem Gewebe. Unbehandelt führt die Erkrankung innerhalb weniger Monate zum Tod. Biologisch ist die ALL heterogen. Genetische und immunphänotypische Marker haben prognostische Bedeutung und sind inzwischen auch prädiktiv für eine Subgruppen-spezifische Therapie. Der Therapieanspruch ist kurativ. Der Standard wird durch die Studien und Expertenempfehlungen der GMALL (German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia) etabliert. Die Langzeitüberlebensraten bei Erwachsenen haben sich in den letzten Jahrzehnten verbessert und liegen mit dem aktuellen Konzept für Patient*innen bis zum Alter von 55 Jahren bei etwa 60-70% mit großer Variationsbreite je nach Alters- und Risikogruppe.
    Subject code 610
    Language German
    Size 1 Online-Ressource (33 Seiten)
    Edition Stand: Mai 2022
    Publisher DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V
    Publishing place Berlin
    Publishing country Germany
    Document type Book ; Online
    Note Open Access
    HBZ-ID HT021565398
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Book: Therapiestudien in der Hämato-Onkologie

    Hehn, Sina / Gökbuget, Nicola

    "soll ich an einer klinischen Studie teilnehmen?" : ein Ratgeber für Patienten mit Leukämien oder Lymphomen

    2014  

    Author's details Autoren: Dr. rer. nat. Sina Hehn & Dr. med. Nicola Gökbuget (KNL)
    Language German
    Size 61 Seiten, 21 cm
    Edition 1. Auflage
    Publisher Stiftung Deutsche Leukämie- & Lymphom-Hilfe ; Kompetenznetz Akute und Chronische Leukämien (KNL) ; Kompetenznetz Maligne Lymphome e.V. (KML)
    Publishing place Bonn ; Frankfurt ; Köln
    Publishing country Germany
    Document type Book
    HBZ-ID HT020048463
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2009 A 11784 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top